	2025	2026	2027	2028	2029
Revenue	1,823,935	2,068,102	2,384,663	2,820,412	3,119,042
Dividend	61.82	72.28	84.54	98.83	113.00
Dividend Yield (in %)	1.43 %	1.67 %	1.96 %	2.29 %	2.62 %
EPS	117.90	139.42	189.22	258.21	284.54
P/E Ratio	36.65	30.99	22.84	16.73	15.19
EBIT	260,264	316,806	433,839	588,879	667,408
EBITDA	331,646	376,061	485,111	600,306	735,350
Net Profit	223,650	263,682	356,176	488,708	546,881
Net Profit Adjusted	239,978	257,251	345,267	445,340	556,750
Pre-Tax Profit	279,071	324,237	433,804	584,045	683,508
Pre-Tax Profit Reported	287,459	321,572	424,845	562,479	925,600
EPS (Non-GAAP) ex. SOE	-	-	-	-	-
EPS (GAAP)	119.41	145.79	181.07	231.36	260.50
Gross Income	1,436,878	1,700,976	1,974,383	2,197,300	2,499,133
Cash Flow from Investing	-108,886	-115,129	-117,226	-82,875	-90,500
Cash Flow from Operations	450,810	409,792	453,311	561,584	618,033
Cash Flow from Financing	-267,932	-150,321	-201,324	-194,505	-218,965
Cash Flow per Share	153.04	179.15	198.74	227.76	230.00
Free Cash Flow	256,387	232,944	267,869	265,171	399,300
Free Cash Flow per Share	46.90	93.95	106.35	186.50	252.80
Book Value per Share	882.20	960.39	1,048.39	1,182.61	1,352.85
Net Debt	-	-	-	-582,370	-727,000
Research & Development Exp.	459,819	517,438	556,723	591,633	610,000
Capital Expenditure	98,474	103,253	100,051	122,849	83,833
Selling, General & Admin. Exp.	856,523	1,016,249	1,168,240	1,213,800	1,477,767
Shareholder’s Equity	1,720,344	1,959,663	2,163,599	2,646,808	3,186,009
Total Assets	3,601,473	3,947,967	4,318,718	4,917,464	5,464,981

	Previous Quarter ending 09/30/24	Current Quarter ending 12/31/24	Next Quarter ending 03/31/25	Current Year ending 03/31/25	Next Year ending 03/31/26
Earnings Estimates
No. of Analysts	-	5	5	15	15
Average Estimate	-	29.411 JPY	18.376 JPY	117.901 JPY	139.419 JPY
Year Ago	-	34.712 JPY	19.383 JPY	104.688 JPY	-
Publish Date	-	-	4/24/2025	-	-
Revenue Estimates
No. of Analysts	-	-	6	15	15
Average Estimate	-	-	474,267 JPY	1,823,935 JPY	2,068,102 JPY
Year Ago	-	-	428,419 JPY	1,601,688 JPY	-
Publish Date	-	-	4/24/2025	-	-

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. JPY

	2024	2023	2022	2021	2020	2019	2018
Sales	1,601,688.00	1,278,478.00	1,044,892.00	962,516.00	981,793.00	929,717.00	960,195.00
Change of sales in %	25.28	22.36	8.56	-1.96	5.60	-3.17	0.53
Gross profit on sales	1,181,795.00	914,953.00	682,090.00	624,227.00	638,587.00	565,112.00	614,174.00
Gross profit on sales change in %	29.16	34.14	9.27	-2.25	13.00	-7.99	1.39
Operating income	186,018.00	121,817.00	82,462.00	80,179.00	118,028.00	90,461.00	112,326.00
Operating income change in %	52.70	47.73	2.85	-32.07	30.47	-19.47	-12.16
Income before tax	237,050.00	126,873.00	73,387.00	73,956.00	141,164.00	85,831.00	81,021.00
Income before tax change in %	86.84	72.88	-0.77	-47.61	64.47	5.94	-7.71
Income after tax	200,731.00	109,188.00	66,972.00	75,957.00	129,074.00	93,410.00	60,282.00
Income after tax change in %	83.84	63.04	-11.83	-41.15	38.18	54.96	12.75

Balance Sheet in Mio. JPY

	2024	2023	2022	2021	2020	2019	2018
Total liabilities	1,772,527.00	1,063,031.00	870,526.00	813,121.00	799,339.00	838,343.00	764,709.00
Long-term liabilities per share	542.23	274.75	244.99	236.65	226.56	233.48	211.84
Equity	1,688,602.00	1,445,854.00	1,350,872.00	1,272,053.00	1,306,273.00	1,249,704.00	1,133,040.00
Equity change in %	16.76	7.03	6.20	-2.59	4.49	10.30	-3.65
Balance sheet total	3,461,129.00	2,508,885.00	2,221,398.00	2,085,174.00	2,105,612.00	2,088,047.00	1,897,749.00
Balance sheet total change in %	37.95	12.94	6.53	-0.97	0.84	10.03	-0.90

Key Data in JPY

	2024	2023	2022	2021	2020	2019	2018
Sales per share	834.80	666.36	544.64	495.64	504.05	477.34	483.69
P/E ratio (year end quote, basic EPS)	45.63	84.66	76.70	82.34	37.32	35.37	38.62
P/E ratio (year end quote, diluted EPS)	45.66	84.73	76.77	82.45	37.39	35.45	38.70
P/E ratio (year end quote)	45.63	84.66	76.70	82.34	37.32	35.37	38.62
Dividend yield in %	1.05	0.62	1.01	0.84	0.94	1.37	1.99
Equity ratio in %	48.79	57.63	60.81	61.00	62.04	59.85	59.70
Debt ratio in %	51.21	42.37	39.19	39.00	37.96	40.15	40.30

DAIICHI SANKYO Dividend Calendar

Date	Name	Dividend	*yield	Currency
2024	DAIICHI SANKYO CO LTDShs	50.00	1.05	JPY
2023	DAIICHI SANKYO CO LTDShs	30.00	0.62	JPY
2022	DAIICHI SANKYO CO LTDShs	27.00	1.01	JPY
2021	DAIICHI SANKYO CO LTDShs	27.00	0.84	JPY
2020	DAIICHI SANKYO CO LTDShs	23.33	0.94	JPY
2019	DAIICHI SANKYO CO LTDShs	23.33	1.37	JPY
2018	DAIICHI SANKYO CO LTDShs	23.33	1.99	JPY
2017	DAIICHI SANKYO CO LTDShs	23.33	2.79	JPY
2016	DAIICHI SANKYO CO LTDShs	23.33	2.80	JPY
2015	DAIICHI SANKYO CO LTDShs	20.00	3.15	JPY
2014	DAIICHI SANKYO CO LTDShs	20.00	3.45	JPY
2013	DAIICHI SANKYO CO LTDShs	20.00	3.31	JPY
2012	DAIICHI SANKYO CO LTDShs	20.00	3.98	JPY
2011	DAIICHI SANKYO CO LTDShs	20.00	3.74	JPY
2010	DAIICHI SANKYO CO LTDShs	20.00	3.43	JPY
2009	DAIICHI SANKYO CO LTDShs	80.00	4.85	JPY

*Yield of the Respective Date

DAIICHI SANKYO Calendar

Event	Estimate	Info	Date
Earnings Report	34.710 JPY	Q3 2024 Earnings Release	01/29/2025
Earnings Report	18.376 JPY	Q4 2025 Earnings Release	04/24/2025
Earnings Report	44.600 JPY	Q1 2025 Earnings Release	07/30/2025
Earnings Report	32.230 JPY	Q2 2025 Earnings Release	10/30/2025

DAIICHI SANKYO Past Events

Event	Actual EPS	Info	Date
Earnings Report	20.860 JPY	Q2 2024 Earnings Release	10/31/2024
Earnings Report	29.740 JPY	Q1 2024 Earnings Release	07/31/2024
Earnings Report	11.730 JPY	Q4 2023 Earnings Release	04/25/2024
Earnings Report	14.810 JPY	Q3 2023 Earnings Release	01/31/2024
Earnings Report	20.580 JPY	Q2 2023 Earnings Release	10/31/2023
Earnings Report	9.840 JPY	Q1 2023 Earnings Release	07/31/2023
Earnings Report	-14.270 JPY	Q4 2022 Earnings Release	04/27/2023
Earnings Report	16.620 JPY	Q3 2022 Earnings Release	01/31/2023
Earnings Report	14.220 JPY	Q2 2022 Earnings Release	10/31/2022
Earnings Report	18.380 JPY	Q1 2022 Earnings Release	07/29/2022
Earnings Report	0.080 JPY	Q4 2021 Earnings Release	04/27/2022
Earnings Report	12.430 JPY	Q3 2021 Earnings Release	01/31/2022

DAIICHI SANKYO Profile

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Moody’s Daily Credit Risk Score

Risk

Low
Medium
High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

DAIICHI SANKYO Shareholder

Owner	in %
Freefloat	85.59
Nomura Asset Management Co., Ltd.	5.19
Nippon Life Insurance Co.	4.41
American Funds EuroPacific Growth Fund	3.62
Daiichi Sankyo Co., Ltd.	3.25
Asset Management One Co., Ltd.	2.86
Nomura Asset NEXT FUNDS TOPIX ETF (1306)	2.83
Vanguard Health Care Fund	1.90
Government Pension Fund - Global (The)	1.69
Nikko Asset Listed Index TOPIX ETF (1308)	1.36
Mizuho Bank Pension Fund	1.28
Shizuoka Financial Group, Inc.	1.28
Mitsubishi UFJ Asset Management Co., Ltd.	1.23
MS&AD Insurance Group Holdings, Inc.	0.85
Sumitomo Mitsui Banking Pension Fund	0.71

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

DAIICHI SANKYO Management

Name	Job
Kenji Sato	Auditor
Miyuki Arai	Auditor
James Felix	Chief Digital Transformation Officer
Akira Ogawa	Chief Financial Officer & Head-Global Planning
Naoki Shimizu	Chief Quality Officer
Takashi Matsumoto	Director & Chief Human Resources Officer
Takashi Fukuoka	Director & Chief Strategy Officer
Sunao Manabe	Executive Chairman & Chief Executive Officer
Naoto Tsukaguchi	General Counsel, Head-Global Legal & IP
Hiroto Kashiwasawa	General Manager-Technology
Matt Allegrucci	Head-Global Compliance & Risk Management
Terumichi Yokoyama	Head-Global Internal Audit
Akio Sakurai	Head-Sales & Marketing Division
Yo Honma	Independent Outside Director
Yasuhiro Komatsu	Independent Outside Director
Kazuaki Kama	Independent Outside Director
Takaaki Nishii	Independent Outside Director
Sawako Nohara	Independent Outside Director
Tomohiro Kodama	Manager-Accounting & Finance
Tetsuya Iwabuchi	Manager-Business Development
Hiroyuki Okuzawa	President, COO & Representative Director
Shoji Hirashima	Representative Director & Senior Executive Officer
Satoshi Ogawa	Secretary
Ueno Shizuko	Senior Exceutive Officer & Head-Medical Affaris
Nobuo Murakami	Senior Executive Officer & Manger-Corporate
Yuki Abe	VP-Research & Development Division